Tarceva Surgery for Resectable Stage IIIA(N2) and IIIB (T4 N2) Non-Small-Cell Lung Cancer
NCT00063258
Terminated
The goal of this clinical research study is to learn about the safety and effectiveness of OSI-774 when combined with standard chemotherapy (carboplatin and paclitaxel) before surgery in the treatment of non-small cell lung cancer.
Gender:
ALL
Ages:
All
Trial Updated:
04/05/2016
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Lung Cancer
Register for Updates
Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the Uterus
NCT00502203
Completed
The goal of this clinical research study is to find out if the combination of paclitaxel and carboplatin chemotherapy can shrink or slow the growth of mixed mullerian tumors (MMMT) of the uterus.
Gender:
FEMALE
Ages:
All
Trial Updated:
04/05/2016
Locations: Lyndon Baines Johnson Hospital, Houston, Texas +1 locations
Conditions: Mixed Tumor, Mullerian
Register for Updates
BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC)
NCT00533585
Completed
The goal of this study is to find the highest tolerable dose of BAY 43-9006 (sorafenib) and bevacizumab that can be given with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC). The safety and effectiveness of this drug combination will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/09/2016
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Lung Cancer
Register for Updates
Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma
NCT01200342
Terminated
The goal of this clinical research is to learn if the combination of Genasense (oblimersen), carboplatin, and paclitaxel (GCP) can help to control metastatic uveal melanoma. The safety of this combination will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/13/2016
Locations: UT MD Anderson Cancer Center, Houston, Texas
Conditions: Melanoma
Register for Updates
Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
NCT00112294
Completed
The primary purpose of this clinical research study is to learn if patients treated with the combination of Taxane/Carboplatin plus Cetuximab (C/T/C) have a longer progression-free survival than patients treated with Taxane/Carboplatin (T/C) alone. The safety of this treatment will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/24/2015
Locations: Local Institution, Amarillo, Texas +3 locations
Conditions: Non-Small-Cell Lung Carcinoma
Register for Updates
Trientine and Carboplatin in Advanced Malignancies
NCT01178112
Completed
The goal of this clinical research study is to find the highest tolerable dose of the combination of trientine and carboplatin that can be given to patients with advanced cancer. The safety of this drug combination will also be studied.
Gender:
ALL
Ages:
All
Trial Updated:
11/16/2015
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced Cancers
Register for Updates
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
NCT00927589
Completed
This Phase Ib, multicenter, single-arm, open-label study is designed to evaluate the effect of trastuzumab on QTcF interval and to characterize the effects of trastuzumab on carboplatin pharmacokinetics in patients with HER2-positive metastatic or locally advanced inoperable cancer. The QT interval is a measure of time between the start of the Q wave and the end of the T wave in the heart's electrical cycle. The QTcF interval is the QT interval as calculated using Fridericia's correction; the Q... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/05/2015
Locations: Not set, Dallas, Texas +5 locations
Conditions: Solid Cancers
Register for Updates
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
NCT00043082
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known if carboplatin is more effective with or without liposomal doxorubicin in treating recurrent ovarian epithelial or primary peritoneal cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of carboplatin with or without liposomal doxorubicin in treating patients who have recurrent o... Read More
Gender:
FEMALE
Ages:
Between 18 years and 120 years
Trial Updated:
10/23/2015
Locations: Harrington Cancer Center, Amarillo, Texas +8 locations
Conditions: Ovarian Cancer, Peritoneal Cavity Cancer
Register for Updates
A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL
NCT00529503
Terminated
This is a randomized trial to estimate the activity of R-ICE plus SGN-40 vs. R-ICE plus placebo in patients with DLBCL. The study will assess safety and tolerability and will measure any additional clinical benefit observed in patients receiving SGN-40.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/06/2015
Locations: Baylor Sammons Cancer Center, Dallas, Texas +1 locations
Conditions: Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin
Register for Updates
Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer
NCT00003313
Completed
RATIONALE: Amifostine may be an effective treatment for the toxic side effects caused by radiation therapy and chemotherapy. It is not yet known whether chemotherapy and radiation therapy are more effective with or without amifostine for non-small cell lung cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of amifostine in treating patients who have stage II or stage III non-small cell lung cancer that cannot be surgically removed and who are undergoing chemotherapy and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/19/2014
Locations: Harrington Cancer Center, Amarillo, Texas +7 locations
Conditions: Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Oral Complications, Radiation Toxicity
Register for Updates
A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma
NCT00111007
Completed
The objectives of this study are to compare the anti-tumor activity as measured by Progression Free Survival (PFS) and tolerability of Sorafenib in combination with Paclitaxel and Carboplatin versus Paclitaxel and Carboplatin in combination with placebo in subjects with unresectable Stage III or Stage IV melanoma who progressed after receiving only one prior therapy containing Dacarbazine (DTIC) or Temozolomide (TMZ).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/23/2014
Locations: Not set, Houston, Texas
Conditions: Melanoma
Register for Updates
Combination Chemotherapy in Treating Children With Neuroblastoma
NCT00003093
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Combination chemotherapy plus surgery may be an effective treatment for neuroblastoma. PURPOSE: This phase III trial is studying how well combination chemotherapy followed by surgery works in treating young patients with neuroblastoma.
Gender:
ALL
Ages:
20 years and below
Trial Updated:
07/31/2014
Locations: Texas Tech University Health Sciences Center School of Medicine, Amarillo, Texas +14 locations
Conditions: Neuroblastoma
Register for Updates